DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spinal cord disease — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpinal cord disease maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spinal cord disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatase and actin regulator 1 (PHACTR1) — PHACTR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 16pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZEE · 1.9 Å · ligand 3,6,9,12,15,18-HEXAOXAICOSANE (16P). Experimental structure, not a prediction.
What the evidence adds up to
A 2005 review of the literature noted that medications such as erythropoietin and minocycline had shown neuroprotective properties in animal models of spinal cord injury, and their established safety in humans made them candidates for clinical trials. The same review stated that human experience with novel neuroprotective and axonal regeneration strategies was growing, but peer-reviewed reporting was anxiously awaited. A 2020 review of 46 articles published between 1990 and 2019 concluded that despite recent advancements, more clinical trials on a larger scale and further research were needed to provide better treatment modalities. Another 2005 review cautioned that reports in the lay press often overwhelmed the paucity of information available in the scientific literature, and expressed cautious optimism that well-designed trials might yield safe and effective treatments.
A 2024 prospective case-control study in Himachal Pradesh with 91 participants compared operative versus conservative treatment for spinal cord injuries over 14 months. The study found that operative treatment significantly improved neurological function and quality of life compared to conservative methods, but with a higher rate of complications. The authors concluded that operative interventions offer more substantial recovery benefits while posing greater risks, and emphasised the need for careful patient selection and management. A 2016 review noted that the number of patients undergoing major spine surgery was increasing, and that outcome assessment in spinal disorders was imperative to help monitor safety and efficacy and to change clinical practice.
No drug repurposing data from human trials are reported in these abstracts. The 2005 mention of erythropoietin and minocycline is limited to animal models and candidate status. What remains missing are large-scale, well-designed human clinical trials for any pharmacological intervention, including repurposed drugs, as well as clear patient stratification to balance the risks of operative treatment against its benefits.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Spine · 2005 · 76 citations
Strategies to Promote Neural Repair and Regeneration After Spinal Cord Injury
AbstractSTUDY DESIGN: Retrospective review of current literature regarding neuroprotection and axonal regeneration therapies for acute spinal cord injury. OBJECTIVES: To provide an update for spine clinicians of the emerging therapeutic strategies for promoting neural repair and regeneration after spinal cord injury. SUMMARY OF BACKGROUND DATA: The neuroscientific community has generated a number of novel potential treatments for spinal injuries, some of which have entered clinical trials. Clinicians who manage spinal cord trauma are likely to encounter patients and their families who have questions or wish to be involved in these emerging treatments. METHODS: Literature review, with particular focus on currently used medications that may have neuroprotective potential in spinal cord injury, and axonal regeneration strategies that are emerging in preliminary human clinical trials. RESULTS: A number of medications such as erythropoietin and minocycline have demonstrated neuroprotective properties in animal models of spinal cord injury, and their long-established safety in humans make them appealing candidates for clinical trials. Human experience with novel neuroprotective and axonal regeneration strategies is growing around the world, and the peer-reviewed reporting of this is anxiously awaited. CONCLUSIONS: The initiation of human clinical trials for spinal cord-injured patients heralds great hope that effective therapies will be forthcoming, although a great deal remains to be learned. Clinicians must provide leadership in the epidemiologic design and rigor of these initial forays into human evaluation.
Surgical Neurology International · 2020 · 52 citations · open access
Current advancements in the management of spinal cord injury: A comprehensive review of literature
AbstractBACKGROUND: Spinal cord injury (SCI) carries debilitating lifelong consequences and, therefore, requires careful review of different treatment strategies. METHODS: An extensive review of the English literature (PubMed 1990 and 2019) was performed regarding recent advances in the treatment of SCI; this included 46 articles written over 28 years. RESULTS: Results of this search were divided into five major modalities; neuroprotective and neuroregenerative pharmaceuticals, neuromodulation, stem cell-based therapies, and various external prosthetic devices. Lately, therapeutic strategies were mainly focused on two major areas: neuroregeneration and neuroprotection. CONCLUSION: Despite recent advancements, more clinical trials on a larger scale and further research are needed to provide better treatment modalities of this devastating neurological disease.
A Review of Current Clinical Trials for Improving Neurological Outcomes
AbstractA new era of clinical spinal cord injury (SCI) research appears to be on the horizon as years of laboratory study are yielding opportunities for application in humans. However, reports in the lay press regarding new treatments often overwhelm the paucity of information available to clinicians and researchers in the scientific literature. An attempt is made to provide a broad overview of some treatments that have garnered public attention, providing references to the scientific and lay literature and concluding with cautious optimism that well-designed clinical trials may yield safe and effective treatments to improve neurological function after SCI.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Comparative Analysis of Operative versus Conservative Treatment for Spinal Cord Injury: A Prospective, Case-Control Study in A Tertiary Care Hospital in Himachal Pradesh
AbstractThis retrospective case-control study at Pt. JLN Govt Medical College, Chamba, Himachal Pradesh, evaluated the outcomes of operative versus conservative treatments for spinal cord injuries over 14 months with 91 participants. The study found that operative treatment significantly improved neurological function and quality of life compared to conservative methods, albeit with a higher rate of complications. These results suggest that while operative interventions offer more substantial recovery benefits, they also pose greater risks, emphasizing the need for careful patient selection and management strategies. This study contributes to the growing body of evidence that supports tailored treatment approaches for spinal cord injuries based on comprehensive risk-benefit analyses.
Journal of Neuroanaesthesiology and Critical Care · 2016 · 0 citations · open access
Improving outcomes in spinal surgery patients
AbstractThe number of patients submitted to major spine surgery is progressively increasing. Surgery on the spine can result in debilitating complications such as neurological deficits, mechanical instability and intractable pain. Outcome is the final output measured as morbidity, mortality and quality of life. Outcome is the result of many interventions during patient course, including economic costs and the importance of an appropriate treatment. Complications are the episodes that may affect patient outcome and may require intervention, further diagnostic tests or monitoring. Outcome assessment in spinal disorders is imperative to help monitor the safety and efficacy of the treatment in an effort to change the clinical practice and improve patient outcomes.
Abstract*Rothman Institute, Philadelphia, PA; and †Delaware Valley Spinal Cord Injury Center, Thomas Jefferson University, Philadelphia, PA. Address correspondence and reprint requests to Alexander R. Vaccaro, MD, PhD, Rothman Institute, 925 Chestnut St., Philadelphia, PA; E-mail: [email protected] Acknowledgment date: December 11, 2012. Acceptance date: December 13, 2012. The manuscript submitted does not contain information about medical device(s)/drug(s). No funds were received in support of this work. Relevant financial activities outside the submitted work: board membership, consultancy, royalties, and stock/stock options.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
